Results 81 to 90 of about 25,067 (205)
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
Profile of olaparib in the treatment of advanced ovarian cancer
, 2016 Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The University of Arizona Cancer Center, 2Division of Gynecologic Oncology, 3Creighton University School of Medicine, St Joseph’s Hospital and Medical Center ...
Chase DM, Shields K, Patel S
core
PET imaging of PARP expression using [18F]olaparib
, 2018 PARP inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization ...
Kersemans, V +31 more
core +1 more source
Olaparib for the treatment of breast cancer
, 2018 Introduction: Mutations in BRCA1 and BRCA2 genes account for around 2–3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase ...
Gaia Griguolo (5042417) +3 more
core +2 more sources
Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Ovarian cancer (OC) is one of the most prevalent and severe gynecological malignant tumors. DNA damage repair (DDR) is essential in maintaining genome stability. This study aims to investigate the effects and mechanisms of USP38 and PLK1 on DNA damage repair and malignant behavior in OC cells.
Yuan Ma, Ying Li, Kai‐Li Li
wiley +1 more source
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
, 2018 Min Wu,1,* Jing Liu,1,* ChuanFei Hu,1 Dong Li,1 Juan Yang,1 ZhouXue Wu,1 LingLin Yang,1 Yue Chen,2 ShaoZhi Fu,1 JingBo Wu1 1Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China; 2Department of Nuclear ...
Wu Z +9 more
core
Precision Medical Sciences, EarlyView.Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik +4 more
wiley +1 more source
Precision Radiation Oncology, EarlyView.The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu +4 more
wiley +1 more source
, 2018 Domenica Lorusso, Elisa Tripodi, Giuseppa Maltese, Stefano Lepori, Ilaria Sabatucci, Giorgio Bogani, Francesco Raspagliesi Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy Abstract: Epithelial ovarian cancer is ...
Lorusso D +6 more
core
, 2019 Aim: Genetic testing for germline BRCA mutation in women with HER2‐negative metastatic breast cancer (MBC) can guide targeted treatment with poly‐ADP‐ribose polymerase (PARP) inhibitors (eg olaparib) and inform cancer prevention strategies (eg risk ...
Scuffham, Paul, Tuffaha, Haitham
core +1 more source